Page 12 - Element Type News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Faricimab meets primary endpoints in phase 3 wet AMD studies Source/Disclosures Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Faricimab met its primary endpoint in tw...

Infectious Disease News | On Feb. 1, 2016, almost 70 years after Zika was first discovered by chance in a forest in Uganda, WHO declared a global public health emergency over an increase in microcephaly and neurological complications linked to the virus.Five years later, despite advances in understanding the transmission, pathogenesis and clinical progression of the mosquito-borne disease, a lot is still unknown about

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.Immunotherapy as monotherapy can offer “excellent benefit” for around 25% to 30% of patients in this setting, or it can be used in combinations to provide

Evolocumab, a PCSK9 inhibitor, in addition to statin therapy for stable atherosclerotic CVD may lower risk for future revascularization with PCI or CABG, according to findings published in the Journal of the American College of Cardiology. As Healio previously reported, in the main results of the FOURIER trial, LDL lowering to a median of 30 mg/dL with evolocumab (Repatha, Amgen) in ASCVD

The FDA granted accelerated approval to daratumumab plus hyaluronidase-fihj in combination with bortezomib, cyclophosphamide and dexamethasone for treatment of newly diagnosed light chain amyloidosis. Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) — a subcutaneous formulation of daratumumab (Darzalex, Janssen) — is approved for several indications for which IV